Recurrent neuroblastoma is a challenging situation where this childhood cancer returns after treatment, requiring different therapeutic approaches and bringing unique concerns for families who have already fought this disease once.

Understanding Recurrent Neuroblastoma

When neuroblastoma comes back after a child has completed treatment and achieved remission, doctors call this recurrent or relapsed neuroblastoma. This situation is different from refractory neuroblastoma, which is when the cancer does not respond to the initial treatment at all. Both conditions represent what medical teams call “resistant disease,” but recurrent neuroblastoma specifically means the cancer has returned after previously disappearing.^[1]

The return of neuroblastoma is unfortunately common in children who were originally diagnosed with high-risk disease. Studies show that approximately half of children treated for high-risk neuroblastoma who achieve an initial remission will experience the disease coming back.^[1] For children initially treated for low-risk or intermediate-risk neuroblastoma, the chance of relapse is much lower, occurring in only about five to fifteen percent of cases.^[14]

The timing of relapse varies, but most recurrences happen within the first two years after completing treatment or undergoing stem cell transplantation. As more time passes without signs of disease, the risk of relapse continues to decrease. Relapses occurring more than five years after treatment completion are quite rare.^[7]

How Common Is Recurrent Neuroblastoma

The frequency of neuroblastoma recurrence depends heavily on the original risk classification of the disease. Children with high-risk neuroblastoma face the greatest challenge. About forty to fifty percent of children with high-risk disease will experience a relapse at some point during or after treatment.^[2] Another ten percent of children with high-risk disease have tumors that never respond to treatment in the first place, developing refractory disease instead.^[2]

In contrast, children whose neuroblastoma was classified as low-risk or intermediate-risk have much lower relapse rates. While these forms may regrow after surgery or chemotherapy, children in these groups are usually cured with standard treatment techniques.^[2]

Historical data from clinical trials conducted between 1991 and 1996 showed that about forty percent of children who reached remission and completed both transplant and maintenance therapy with Accutane eventually relapsed. Since that time, treatment has become more intensive, and additional therapies such as immunotherapy have been added, which may have reduced the overall risk of relapse.^[7]

Why Neuroblastoma Returns

No one has definitively determined what causes neuroblastoma to return after a child has achieved clinical remission. The exact biological mechanisms remain unclear, but researchers have developed several theories to explain why the cancer might come back despite aggressive treatment.^[7]

One theory suggests that neuroblastoma cells might be accidentally reintroduced into the child’s body through contaminated stem cells (special cells collected from the child’s blood or bone marrow and frozen for later use) during the stem cell rescue procedure that follows high-dose chemotherapy. If even a small number of cancer cells were present in the collected stem cells, they could potentially restart the disease.^[7]

Another possibility is that some neuroblastoma cells find hiding places in what doctors call “sanctuary sites” in the body. These are areas where chemotherapy and other treatments may not reach effectively, such as the brain or testes. Cancer cells hiding in these protected locations could survive treatment and later begin growing again.^[7]

A third theory involves the development of treatment resistance. Some neuroblastoma cells may develop the ability to resist or survive chemotherapy and other treatments. These resistant cells could persist in very small numbers, undetectable by current scanning and testing methods, and later multiply to cause a clinical relapse.^[7]

It is important to understand that tumors often emerge and behave in ways that have no clear external cause. Many cancers, including neuroblastoma, result from complex interactions between genetic factors within the tumor cells themselves and various environmental influences. Some cancers are linked to inherited genetic conditions, but most cases occur without any identifiable inherited risk factor.^[1]

Where Neuroblastoma Recurs in the Body

Neuroblastoma can return in the same location where it originally developed, or it can appear in entirely new locations throughout the body. The pattern and location of recurrence significantly affect both the treatment approach and the child’s outlook.^[9]

In general, when the disease recurs in only one area of the body, the prognosis tends to be better than when it returns in multiple locations. A localized relapse confined to a single site is often more treatable than widespread disease affecting bones and bone marrow.^[9]

Just like the original neuroblastoma, recurrent tumors most commonly develop in areas where sympathetic nervous system tissue is present. This includes the adrenal glands (small organs that sit on top of the kidneys), as well as nerve tissues running along the spine in the neck, chest, abdomen, or pelvis. Recurrent neuroblastoma frequently spreads to lymph nodes, liver, bones, and bone marrow. In adolescents, spread to the lungs and brain may also occur.^[1]

Recognizing Signs of Recurrent Neuroblastoma

The symptoms of recurrent neuroblastoma vary greatly depending on where the tumor has returned and how large it has grown. In many ways, the symptoms mirror those seen when neuroblastoma is first diagnosed, but the specific signs depend on the tumor’s location and whether it has spread to other parts of the body.^[1]

Sometimes relapse is detected on routine follow-up imaging scans before any symptoms appear at all. This is one reason why regular monitoring after completing treatment is so important. Pain is considered the most common symptom when relapse does cause noticeable problems, but there are many other potential warning signs.^[2]

Common symptoms that may indicate neuroblastoma has returned include:

• A mass or lump in the abdomen that can be felt or causes visible swelling
• Enlarged lymph nodes in the neck that appear as lumps
• Swelling and bruising around the eyes, sometimes creating dark circles
• Unexplained fevers that persist without clear cause
• Bone pain or limping that cannot be explained by recent injury
• Weakness or paralysis affecting the ability to move parts of the body
• Unintended weight loss or poor appetite
• Uncontrolled eye movements or involuntary leg movements
• Unusual fatigue or tiredness
• New areas of swelling anywhere in the body

These symptoms can also be caused by many other conditions that are not cancer. However, any concerning signs in a child who has previously been treated for neuroblastoma should be reported to the medical team promptly for evaluation.^[1]

Diagnosing Recurrent Neuroblastoma

After completing initial neuroblastoma treatment, children typically have regularly scheduled scans and follow-up appointments for about three years. These surveillance visits are specifically designed to detect any signs of relapse as early as possible. The medical team remains vigilant during this monitoring period because early detection of recurrence can sometimes improve treatment options.^[2]

If a relapse is suspected based on symptoms or abnormal findings on routine scans, the doctor will order a series of tests to confirm whether the cancer has returned and to determine the extent of disease. These diagnostic tests serve multiple purposes: confirming that neuroblastoma is truly present, identifying all locations where cancer may have returned, and gathering biological information about the tumor that can guide treatment decisions.^[1]

Common tests used to diagnose recurrent neuroblastoma include:

• Computerized tomography (CT or CAT) scans that use X-rays to create detailed cross-sectional images of the body
• Magnetic resonance imaging (MRI) scans that use magnetic fields and radio waves to produce detailed pictures of soft tissues
• Bone scans that can detect cancer that has spread to the bones
• Metaiodobenzylguanidine (MIBG) scans, a specialized nuclear medicine test where a small amount of radioactive substance that neuroblastoma cells absorb is injected into the bloodstream, allowing the tumors to light up on special imaging
• Bone marrow biopsy and aspiration, procedures where a needle is used to remove small samples of bone marrow (the spongy tissue inside bones where blood cells are made) to examine under a microscope for cancer cells
• Urine tests to measure certain chemicals called catecholamines that neuroblastoma cells often produce
• Blood tests to check for various markers and to assess overall health

In some cases, doctors may recommend a tumor biopsy, where a piece of the tumor or the entire tumor is surgically removed. This tissue is then analyzed by specialists called pathologists who examine it under a microscope. Additional sophisticated tests may be performed on the tumor tissue to look for genetic changes that could affect treatment choices and help predict how the cancer might behave.^[1]

Treatment Options for Recurrent Neuroblastoma

Treating neuroblastoma that has returned after previous therapy presents significant challenges. The cancer has already proven it can survive intensive treatment, and the child’s body may have experienced lasting effects from the first round of therapy that limit what additional treatments can safely be given. Despite these challenges, multiple treatment options exist, and some children with recurrent neuroblastoma can achieve long-term survival.^[11]

The specific treatment recommended depends on numerous factors, including the original risk group classification, where the cancer has returned, what treatments the child received previously, how much time has passed since completing initial therapy, and the child’s overall health and ability to tolerate further treatment.^[9]

Treatment for Low-Risk and Intermediate-Risk Relapse

Children who were initially diagnosed with low-risk or intermediate-risk neuroblastoma and experience a relapse in a single, localized area may be treated with surgery to remove the recurrent tumor. Sometimes chemotherapy is added, either before surgery to shrink the tumor or after surgery to eliminate any remaining cancer cells.^[9]

If the recurrent low-risk neuroblastoma has spread to multiple areas of the body, treatment typically involves chemotherapy. Various drug combinations may be used, including regimens with carboplatin, cyclophosphamide, doxorubicin, etoposide, topotecan, irinotecan, and temozolomide.^[9]

For intermediate-risk recurrence that has spread widely, treatment often becomes more aggressive and may include a combination of chemotherapy, surgery, radiation therapy, stem cell rescue, retinoids (vitamin A-related medications), and immunotherapy drugs.^[9]

Treatment for High-Risk Relapse

Children originally treated for high-risk neuroblastoma who experience relapse require particularly intensive approaches. Treatment usually involves combining multiple different therapies. The type of chemotherapy used for relapse is typically different from what was given during initial treatment, as the cancer has already been exposed to those drugs.^[5]

One of the most effective treatment regimens for relapsed high-risk disease combines chemotherapy with immunotherapy. Common chemotherapy combinations include temozolomide with irinotecan (sometimes given with an immunotherapy drug called dinutuximab), or topotecan with cyclophosphamide.^[9]

Another treatment option is targeted radiotherapy using MIBG. In this approach, the child receives a higher dose of radioactive iodine than used for diagnostic scanning. The neuroblastoma cells absorb this radioactive substance and are killed by the radiation. This treatment is only available at specialized medical centers and is often given as part of a clinical trial. Following this intensive treatment, stem cell rescue may be necessary to help the bone marrow recover.^[5]

Some children may receive additional treatments such as immunotherapy drugs (like dinutuximab beta) or 13-cis-retinoic acid (isotretinoin), a substance related to vitamin A that can help prevent neuroblastoma cells from growing.^[5]

Novel and Investigational Therapies

Because outcomes for children with recurrent neuroblastoma remain challenging, researchers are actively studying new treatment approaches. Many of these investigational therapies are available through clinical trials, and doctors may suggest enrollment in a trial testing newer treatments.^[5]

Targeted cancer drugs work by attacking specific differences in cancer cells that help them grow and survive. Scientists are investigating several targeted drugs for relapsed neuroblastoma. For example, ALK inhibitors (such as crizotinib, lorlatinib, and entrectinib) target neuroblastoma cells that have an abnormal ALK gene. These drugs may be used to treat neuroblastoma that is no longer responding to other treatments when laboratory tests show the tumor has an ALK gene abnormality.^[5]

Bevacizumab is a type of targeted drug called a monoclonal antibody that works by cutting off the tumor’s blood supply. Research has shown that children with relapsed or refractory neuroblastoma may benefit from bevacizumab combined with chemotherapy drugs like irinotecan and temozolomide, or topotecan and cyclophosphamide.^[5]

Other targeted drugs being studied include venetoclax, idasanutlin, and LY3295668. Researchers are investigating these medications both alone and in combination with chemotherapy.^[5]

Scientists have also been examining a novel drug called pegylated recombinant human arginase (BCT-100). This medication works by lowering levels of arginine, an important protein that cancer cells need to grow and divide. By depleting arginine, researchers hope to starve cancer cells and stop them from growing.^[5]

Outlook and Survival

The outlook for children with recurrent neuroblastoma varies considerably depending on multiple factors. In the past, relapsed neuroblastoma was considered invariably fatal, but more recent data suggests that a subset of patients with recurrent disease can achieve long-term survival with appropriate treatment.^[11]

Several factors influence prognosis after relapse. The timing of recurrence matters significantly. Children who relapse earlier, particularly during treatment or shortly after completing therapy, generally face greater challenges than those whose cancer returns years later. The location and extent of recurrence also plays a major role. Children with isolated local recurrence confined to a single area tend to have better outcomes than those with widespread disease affecting multiple sites, particularly bones and bone marrow.^[11]

The original risk classification also affects outcomes after relapse. Children initially diagnosed with low-risk or intermediate-risk disease who experience relapse generally have better survival rates than those who relapse after high-risk disease treatment. The overall survival for children after initial relapse has been reported at about twenty percent at five years, though this varies significantly based on the factors mentioned above.^[11]

For children with localized relapse, particularly those who were initially in lower risk groups, treatment with surgical removal of the tumor and possibly radiation therapy can sometimes lead to cure. Recent reports indicate that patients with isolated local recurrence can be treated successfully with these approaches.^[11]

How the Body Changes with Recurrent Disease

When neuroblastoma returns, it causes changes in the body’s normal functioning similar to those seen with newly diagnosed disease, but sometimes complicated by effects from previous treatment. Understanding these changes helps explain why symptoms occur and why certain treatments are necessary.^[11]

Neuroblastoma cells grow abnormally and form tumors that can physically press on nearby organs, nerves, and blood vessels. When a tumor presses on nerves, it can cause pain or interfere with nerve signals, leading to weakness or even paralysis. Tumors in the abdomen can press on the stomach or intestines, causing poor appetite or digestive problems. Tumors near the spine can compress the spinal cord, which is a medical emergency requiring immediate treatment.^[3]

When neuroblastoma spreads to the bones, cancer cells multiply within the bone structure, causing pain and making bones more fragile. Spread to bone marrow disrupts the normal production of blood cells. The bone marrow, which normally produces red blood cells, white blood cells, and platelets, cannot function properly when invaded by cancer cells. This leads to anemia (low red blood cells causing fatigue), increased infection risk (low white blood cells), and bleeding or bruising problems (low platelets).^[11]

Many neuroblastoma cells produce substances called catecholamines, which are chemicals normally made in small amounts by the adrenal glands. When neuroblastoma produces excessive amounts of these chemicals, they can be detected in urine tests and may cause symptoms such as high blood pressure, rapid heart rate, and sweating.^[3]

Recurrent neuroblastoma also affects the body’s immune system and metabolism. Cancer cells consume nutrients and energy that the body needs for normal growth and function, which can lead to weight loss and weakness. The presence of cancer can trigger the body to produce inflammatory chemicals that cause fever and contribute to the general feeling of illness many patients experience.^[11]